1. Home
  2. CUE vs CEV Comparison

CUE vs CEV Comparison

Compare CUE & CEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • CEV
  • Stock Information
  • Founded
  • CUE 2014
  • CEV 1999
  • Country
  • CUE United States
  • CEV United States
  • Employees
  • CUE N/A
  • CEV N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • CEV Finance/Investors Services
  • Sector
  • CUE Health Care
  • CEV Finance
  • Exchange
  • CUE Nasdaq
  • CEV Nasdaq
  • Market Cap
  • CUE 58.9M
  • CEV 67.8M
  • IPO Year
  • CUE 2018
  • CEV N/A
  • Fundamental
  • Price
  • CUE $0.77
  • CEV $9.83
  • Analyst Decision
  • CUE Strong Buy
  • CEV
  • Analyst Count
  • CUE 3
  • CEV 0
  • Target Price
  • CUE $3.00
  • CEV N/A
  • AVG Volume (30 Days)
  • CUE 159.5K
  • CEV 19.6K
  • Earning Date
  • CUE 05-20-2025
  • CEV 01-01-0001
  • Dividend Yield
  • CUE N/A
  • CEV 4.23%
  • EPS Growth
  • CUE N/A
  • CEV N/A
  • EPS
  • CUE N/A
  • CEV 0.36
  • Revenue
  • CUE $9,287,000.00
  • CEV N/A
  • Revenue This Year
  • CUE N/A
  • CEV N/A
  • Revenue Next Year
  • CUE $25.99
  • CEV N/A
  • P/E Ratio
  • CUE N/A
  • CEV $29.36
  • Revenue Growth
  • CUE 69.16
  • CEV N/A
  • 52 Week Low
  • CUE $0.45
  • CEV $8.83
  • 52 Week High
  • CUE $2.26
  • CEV $10.91
  • Technical
  • Relative Strength Index (RSI)
  • CUE 44.09
  • CEV 53.65
  • Support Level
  • CUE $0.71
  • CEV $9.74
  • Resistance Level
  • CUE $0.78
  • CEV $9.88
  • Average True Range (ATR)
  • CUE 0.06
  • CEV 0.08
  • MACD
  • CUE 0.01
  • CEV 0.04
  • Stochastic Oscillator
  • CUE 38.26
  • CEV 86.84

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest

Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.

Share on Social Networks: